Clinical trials: With/Without Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2, Overweight
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal.
- Conditions
- Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT07299084
- Testing
- Tirzepatide
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07670416
- Testing
- Enicepatide
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus Type 2
Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion
The hypoglycemic effect of Momordica Charantia has been evaluated in clinical trials in patients with type 2 diabetes mellitus. Important reductions in fasting plasma glucose, glycated hemoglobin (A1C), and fructosamine were…
- Trial name
- NCT02397447
- Testing
- Momordica charantia
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Periodontal Diseases
Quantification of Proteomes: L-plastin , Lipocalin and Adiponectin in Chronic Periodontitis and Diabetic Subjects
The quantification of the proteomes : L-plastin, lipocalin and adiponectin was analysed in the subgingival tissue samples of generalized severe chronic periodontitis patients with and without diabetes mellitus.The demographic and…
- Trial name
- NCT03391349
- Volunteers
- 70 people
- Sponsor
- Meenakshi Ammal Dental College and Hospital
Advanced Sarcoma, Metastatic Sarcoma
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma…
- Conditions
- Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT05448820
- Testing
- YH001, Envafolimab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Diabetes Mellitus Type 2 Without Complication
Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes
To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity.
- Trial name
- NCT05109949
- Testing
- Dapagliflozin 10Mg Tab, Empagliflozin 25 MG
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Type II Diabetes Mellitus
Evaluate the Side Effects and Benefits of RAS 130 With or Without Diet and Exercise in Type II Diabetes Mellitus
Rationale: RAS 130 is an anti-diabetic agent used to lower the blood glucose level in Type II Diabetes mellitus (non-insulin-dependent diabetes) patients with proper diet and exercise.
- Trial name
- ASI-DMII (NCT00737152)
- Testing
- RAS 130 with diet and exercise
- Where
- 5 sites in United States, India
- Volunteers
- 460 people
- Sponsor
- American Scitech International
Diabetes Mellitus
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
Study D5553C00002 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to compare the safety and efficacy of exenatide once weekly (EQW) added to titrated basal insulin glargine with or…
- Trial name
- NCT02229383
- Testing
- Exenatide
- Where
- 123 sites in United States, Hungary and 4 more
- Volunteers
- 464 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Blod Pressure
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus
Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected.
- Conditions
- Type 2 Diabetes, Blod Pressure, Glucagon-like Peptide-1, Human Physiology
- Trial name
- NCT01689051
- Testing
- human glucagon-like peptide 1 (7-36)amide, human glucagon-like peptide 1 (9-36)amide
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2, Healthy
Sedentary Behavior in Older Women With and Without Type 2 Diabetes
Sedentary behavior has been linked to cardiovascular morbidity and mortality, and is particularly common in older adults with type 2 diabetes.
- Trial name
- SitWise (NCT04262128)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan
The primary purpose of this study is to describe the tolerability of canagliflozin and any sulphonylurea (each administered with metformin with or without a DPP-4 inhibitor), in terms of the percentage of patients with at least…
- Trial name
- CRATOS (NCT02737657)
- Where
- 9 sites in Kuwait, Lebanon and 1 more
- Volunteers
- 379 people
- Sponsor
- Janssen-Cilag International NV
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.
This study was designed to test the safety and efficacy (how well it works) of AVANDAMET in combination with insulin in improving the control of blood sugar when compared with taking insulin on its own.
- Trial name
- NCT00069836
- Testing
- Rosiglitazone/metformin
- Where
- 93 sites in Austria, France and 3 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Obesity, Type 2 Diabetes Mellitus (T2DM)
Magnetic Duodeno-Ileal Chile Study
The objective of the MagDI Chile Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Trial name
- NCT06613724
- Testing
- Magnet System, DI Biofragmentable
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- GT Metabolic Solutions, Inc.
Type 2 Diabetes
Diet With or Without Metarecod® in Obese Subjects With Type 2 Diabetes
Obesity is considered the largest chronic non-communicable disease (globesity) worldwide with a growing trend in the near future.
- Trial name
- MONDO (NCT06813170)
- Testing
- Metarecod, Diet
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19, Type 2 Diabetes Mellitus
Effects of Telerehabilitative Aerobic and Relaxation Exercises Patients With Type 2 Diabetes With and Without COVID-19
Type-2 Diabetes Mellitus (DM) disease, like other chronic diseases, is a group of diseases that are adversely affected by the COVID-19 pandemic.This study was planned to examine the effect of COVID-19 disease on patients with…
- Trial name
- NCT05411458
- Testing
- Aerobic and Relaxation Exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Bozyaka Training and Research Hospital
Diabetes, Bariatric Surgery
Comparison Between Patients With or Without Diabetes Recovery After Bariatric Surgery
Bariatric surgery can lead to improvement or even resolution of type 2 diabetes in about 80% of patients submitted to Roux-en-Y gastric bypass (RYGP).
- Conditions
- Diabetes, Bariatric Surgery, Obesity
- Trial name
- NCT00834938
- Testing
- No intervention
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Diabetic Foot Ulcer, Diabetic Neuropathy
Differential Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds
The primary purpose of this study is to determine the degree of loss of epidermal nerve fibers near a foot wound in patients with diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcer, Diabetic Neuropathy, Type 2 Diabetes
- Trial name
- NCT02347709
- Testing
- Diabetic Foot Ulcer Biopsy, Survey, Comprehensive Neuropathy Assessment
- Where
- United States
- Sponsor
- Winthrop University Hospital
Obesity, Overweight
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
- Trial name
- MARITIME-PEN (NCT07871409)
- Testing
- Maridebart cafraglutide, Autoinjector
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
Safety and Performance of the Glyconics-SX System
The main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the Glyconics-SX System in distinguishing between individuals with or without T2DM based on known and/or…
- Trial name
- ANODE01 (NCT05198895)
- Testing
- Near-infrared (NIR)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Glyconics Ltd